SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Incannex Healthcare Limited IXHL NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • AU • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Incannex Healthcare Limited (IXHL) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $3.54. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Valuation: IXHL trades at a trailing Price-to-Earnings (P/E) of -0.6 (S&P 500 average ~25).

Financials: revenue is $86,000, +258.3%/yr average growth. Net income is $47M (loss), growing at -155.4%/yr. Net profit margin is -54517.4% (negative). Gross margin is 100% (+0.8 pp trend).

Balance sheet: total debt is $258,000 against $13M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 2.86 (strong liquidity). Debt-to-assets is 1.3%. Total assets: $20M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

IXHL SharesGrow Score Overview

45/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 46/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IXHL

No analyst coverage available for this stock.

IXHL: +258.3%/yr revenue is, -155.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet IXHL: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 2.86 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

IXHL: Gross margin is 100% (+0.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

IXHL: Net profit margin is -54517.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range2.4-49.8

Volume495.8K

Avg Volume (30D)496.6K

Market Cap$40.66M

Beta (1Y)2.73

Share Statistics

EPS (TTM)-40.80

Shares Outstanding$1.15M

IPO Date2022-03-02

Employees9

CEOJoel Bradley Latham

Financial Highlights & Ratios

Revenue (TTM)$86K

Gross Profit$86K

EBITDA$-48.09M

Net Income$-46.89M

Operating Income$-23.79M

Total Cash$15.04M

Total Debt$258K

Net Debt$-14.78M

Total Assets$20.45M

Price / Earnings (P/E)-0.1

Price / Sales (P/S)472.74

Analyst Forecast

Company Info

CountryAU

ExchangeNASDAQ Global Market

CurrencyUSD

ISINUS45333F2083

Price Chart

IXHL

Incannex Healthcare Limited ↗ · NASDAQ Global Market

Healthcare • Drug Manufacturers - Specialty & Generic

2.40 52WK RANGE 49.80

People Also View

Regencell Bioscience Holdings Limited

Prestige Consumer Healthcare Inc.

Phibro Animal Health Corporation

Deciphera Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc.

Sihuan Pharmaceutical Holdings Group Ltd.

Collegium Pharmaceutical, Inc.

Procaps Group S.A.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message